BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37285748)

  • 1. Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors.
    Mundra V; Yang Y; von Itzstein MS; Fattah F; Gonugunta AS; Hannan R; Pop LM; Zhang Y; Wang Y; Sheffield T; Xie Y; Dowell JE; Homsi J; Rashdan S; Park J; Li QZ; Wakeland EK; Gerber DE
    Transl Oncol; 2023 Aug; 34():101689. PubMed ID: 37285748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.
    von Itzstein MS; Gonugunta AS; Sheffield T; Homsi J; Dowell JE; Koh AY; Raj P; Fattah F; Wang Y; Basava VS; Khan S; Park JY; Popat V; Saltarski JM; Gloria-McCutchen Y; Hsiehchen D; Ostmeyer J; Xie Y; Li QZ; Wakeland EK; Gerber DE
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
    Hubbeling HG; Schapira EF; Horick NK; Goodwin KEH; Lin JJ; Oh KS; Shaw AT; Mehan WA; Shih HA; Gainor JF
    J Thorac Oncol; 2018 Apr; 13(4):550-558. PubMed ID: 29378267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
    Tracz JA; Donnelly BM; Ngu S; Vojnic M; Wernicke AG; D'Amico RS
    J Neurooncol; 2023 May; 163(1):1-14. PubMed ID: 37086369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database.
    Anscher MS; Arora S; Weinstock C; Amatya A; Bandaru P; Tang C; Girvin AT; Fiero MH; Tang S; Lubitz R; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    JAMA Oncol; 2022 Feb; 8(2):232-240. PubMed ID: 34989781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy.
    Guan H; Zhou Z; Hou X; Zhang F; Zhao J; Hu K
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):35-50. PubMed ID: 35538049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis.
    Sha CM; Lehrer EJ; Hwang C; Trifiletti DM; Mackley HB; Drabick JJ; Zaorsky NG
    Radiother Oncol; 2020 Oct; 151():141-148. PubMed ID: 32717359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy.
    Son C; Moey MYY; Walker PR; Naqash AR; Peach MS; Ju AW
    Front Oncol; 2022; 12():1025455. PubMed ID: 36698405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model.
    Song HN; Jin H; Kim JH; Ha IB; Kang KM; Choi HS; Jeong HJ; Kim MY; Kim HJ; Jeong BK
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer.
    Lee KE; Bender DA; Koutcher LD; Hyde B; Hur C; Faye AS; Cheng SK
    Cancer; 2022 Feb; 128(4):819-827. PubMed ID: 34634130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
    Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
    Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer.
    Sumodhee S; Guo L; Bouhlel L; Picard A; Otto J; Naghavi AO; Richier Q; Lévy A; Bondiau PY; Poudenx M; Passeron T; Lacour JP; Montaudié H; Doyen J
    Cancer Radiother; 2022 Nov; 26(8):1045-1053. PubMed ID: 35927166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
    Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
    Samuel E; Lie G; Balasubramanian A; Hiong A; So Y; Voskoboynik M; Moore M; Shackleton M; Haydon A; John T; Mitchell PLR; Markman B; Briggs P; Parakh S
    Clin Lung Cancer; 2021 May; 22(3):e425-e430. PubMed ID: 32778511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition.
    Trommer M; Yeo SY; Persigehl T; Bunck A; Grüll H; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Herter JM; Celik E; Marnitz S; Baues C
    Front Pharmacol; 2019; 10():511. PubMed ID: 31156434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer.
    Ho AY; Tabrizi S; Dunn SA; McArthur HL
    Breast Cancer Res Treat; 2022 Jan; 191(2):229-241. PubMed ID: 34714450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases.
    Su Z; Zhou L; Xue J; Lu Y
    Chin J Cancer Res; 2020 Aug; 32(4):448-466. PubMed ID: 32963458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.